News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Lundbeck Inc. Won’t Restrict Drug’s Use for U.S. Executions
March 31, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Dispath -- A Danish company that unwittingly has become a key supplier of an execution drug in the U.S. says it's not going to withdraw or restrict it, even though it objects to the chemical's being "misused" for capital punishment.
Twitter
LinkedIn
Facebook
Email
Print
Europe
Lundbeck
MORE ON THIS TOPIC
Insights
The Golden Triangle and the gaps: Rethinking UK biotech
June 25, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Insights
Beyond sunshine: Iberia’s biotech moment has arrived with developing capital networks
June 12, 2026
·
4 min read
·
Jennifer C. Smith-Parker
Insights
Portugal, Spain and the new biotech frontier
June 11, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Job Trends
May layoffs hit nearly 7,000, with most cuts from Takeda, BioNTech
June 11, 2026
·
3 min read
·
Angela Gabriel